Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Criticism of the HAS Opinion of July 21st, 2022, on Maintaining of the SARS-Cov-2 Vaccine Mandate for Healthcare Workers

Author(s): Jérôme Sainton*

Volume 4, Issue 2, 2023

Published on: 22 August, 2023

Article ID: e040823219432 Pages: 6

DOI: 10.2174/2666796704666230804103419

Price: $65

Abstract

The opinion of the French National Authority for Health (HAS) on July 21st, 2022, concluded that the mechanism of the SARS-Cov-2 vaccine mandate for caregivers and other health professionals should be maintained. Constructed as a syllogism, the opinion states that the benefit-risk balance of a three-dose vaccination schedule to limit transmission is favorable (major premise) and that this balance necessarily determines the mechanism of SARS-Cov-2 vaccine mandate (minor premise) so that it should be maintained (conclusion). Each of these steps is flawed. First, the benefit-risk analysis of a three-dose vaccination schedule is many times distorted: it fails to transpose the relative efficacy of the vaccination in terms of absolute efficacy; it fails to take into account both the particularly poor efficacy of the vaccination against the risk of infection (symptomatic or not) and its decrease, or even negativation, over time, as well as the worsening of the vaccine escape with the latest Omicron sub-lineages; it does not assess the risk associated with the mechanism, particularly with regard to COVID convalescents and pregnant women. Secondly, the inference made from this analysis to the specific mechanism of mandatory vaccination of caregivers is distorted. There is no refocusing on the specific population of caregivers, and the real and concrete benefit of the mechanism itself is not measured. Thirdly, the very construction of the reasoning is distorted. By reducing a medical problem to the calibration of a strictly technical benefit- risk balance, it evades the intrinsic practical and ethical dimensions of the issue.

Graphical Abstract

[1]
Avis HAS. Opinion n°2022.0044/AC/SESPEV of July 21, 2022 of the College of the High Authority for Health relating to the obligation of vaccination against COVID-19 for professionals in the health and medico-social sectors. 2022. Available from: https://has-sante.fr/jcms/p_3356224/fr
[2]
Avis HAS. Opinion n°2022.0043/AC/SESPEV of July 13, 2022 of the College of the High Authority for Health relating to the place of an additional booster dose of vaccines against COVID-19 in the vaccine strategy. 2022. Available from: https://www.has-sante.fr/jcms/p_3352538/fr
[3]
Fischhoff B, Brewer NT, Downs JS. Communicating risks and Benefits: An evidence-based user’s guide. Food and Drug Administration 2011; p. 242.
[4]
Brown RB. Outcome reporting bias in COVID-19 mRNA vaccine clinical trials. Medicina 2021; 57(3): 199.
[http://dx.doi.org/10.3390/medicina57030199] [PMID: 33652582]
[5]
Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: A systematic review and pooled analysis. Cureus 2021; 13(10): e19102.
[http://dx.doi.org/10.7759/cureus.19102] [PMID: 34868754]
[6]
Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: A retrospective, total population cohort study in Sweden. Lancet 2022; 399(10327): 814-23.
[http://dx.doi.org/10.1016/S0140-6736(22)00089-7] [PMID: 35131043]
[7]
Avis HAS. Opinion n° 2021.0052/AC/SEESP of July 15, 2021 of the College of the High Authority for Health relating to the bill relating to the adaptation of our health crisis management tools. 2021. Available from: https://has-sante.fr/jcms/p_3278245/fr
[8]
HAS. COVID-19: the vaccination obligation provided for by law is justified and its extension must be debated. Available from: https://www.has-sante.fr/jcms/p_3278138/fr
[9]
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N Engl J Med 2022; 386(19): 1804-16.
[http://dx.doi.org/10.1056/NEJMoa2200797] [PMID: 35263534]
[10]
Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med 2022; 386(16): 1532-46.
[http://dx.doi.org/10.1056/NEJMoa2119451] [PMID: 35249272]
[11]
El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021; 385(19): 1774-85.
[http://dx.doi.org/10.1056/NEJMoa2113017]
[12]
Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385(19): 1761-73.
[http://dx.doi.org/10.1056/NEJMoa2110345]
[13]
Buchan SA, Chung H, Brown KA, et al. Estimated effectiveness of COVID-19 vaccines against omicron or delta symptomatic infection and severe outcomes. JAMA Netw Open 2022; 5(9): e2232760.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.32760]
[14]
Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against omicron or delta infection. medRxiv
[http://dx.doi.org/10.1101/2021.12.30.21268565]
[15]
Boucau J, Marino C, Regan J, et al. Duration of shedding of culturable virus in SARS-CoV-2 omicron (BA.1) infection. N Engl J Med 2022; 387(3): 275-7.
[http://dx.doi.org/10.1056/NEJMc2202092] [PMID: 35767428]
[16]
DREES. Vaccination status of people tested or hospitalized with COVID-19 – Data as of July 1, 2022. Research, studies, evaluation and statistics department. 2022. Available from: https://drees.solidarites-sante.gouv.fr/communique-de-presse/statut-vaccinal-des-personnes-testees-ou-hospitalisees-avec-COVID-19-donnees-0
[17]
UK Health Security Agency. COVID-19 Vaccine Surveillance Report - Week 41.; 2021. 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1025358/Vaccine-surveillance-report-week-41.pdf
[18]
Emani VR, Pallipuram VK, Goswami KK, et al. Increasing SARS-CoV2 cases, hospitalizations and deaths among the vaccinated elderly populations during the Omicron (B.1.1.529) variant surge in UK. medRxiv
[http://dx.doi.org/10.1101/2022.06.28.22276926]
[19]
Statens Serum Institut. COVID-19 Gennembrudsinfektioner Og Vaccineeffektivitet 2022. Available from: https://files.ssi.dk/COVID-19/gennembrudsinfektion/rapport/gennembrudsinfektion-COVID19-uge01-2022-dk30
[20]
Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun 2022; 13(1): 3082.
[http://dx.doi.org/10.1038/s41467-022-30895-3] [PMID: 35654888]
[21]
Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): A national cohort study with nested test-negative design. Lancet Infect Dis 2022; 22(7): 959-66.
[http://dx.doi.org/10.1016/S1473-3099(22)00141-4] [PMID: 35468332]
[22]
Chemaitelly H, Ayoub HH, Tang P, et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: A retrospective population-based cohort study. Lancet Infect Dis 2023; 23(7): 816-27.
[http://dx.doi.org/10.1016/S1473-3099(23)00058-0] [PMID: 36913963]
[23]
Tseng HF, Ackerson BK, Bruxvoort KJ, et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun 2023; 14(1): 189.
[http://dx.doi.org/10.1038/s41467-023-35815-7] [PMID: 36635284]
[24]
Röltgen K, Nielsen SCA, Silva O, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 2022; 185(6): 1025-1040.e14.
[http://dx.doi.org/10.1016/j.cell.2022.01.018] [PMID: 35148837]
[25]
Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol 2022; 164: 113008.
[http://dx.doi.org/10.1016/j.fct.2022.113008]
[26]
Shimizu J, Sasaki T, Koketsu R, et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci Rep 2022; 12(1): 15612.
[http://dx.doi.org/10.1038/s41598-022-19993-w] [PMID: 36114224]
[27]
Irrgang P, Gerling J, Kocher K, et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol 2023; 8(79): eade2798.
[http://dx.doi.org/10.1126/sciimmunol.ade2798] [PMID: 36548397]
[28]
Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022; 608(7923): 603-8.
[http://dx.doi.org/10.1038/s41586-022-05053-w] [PMID: 35790190]
[29]
Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022; 608(7923): 593-602.
[http://dx.doi.org/10.1038/s41586-022-04980-y]
[30]
Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022; 387(1): 86-8.
[http://dx.doi.org/10.1056/NEJMc2206576] [PMID: 35731894]
[31]
ANSM. News - Update on the monitoring of vaccines against COVID-19 - Period from 24/05/2022 to 16/06/2022. 2022. Available from: https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-COVID-19-periode-du-24-05-2022-au-16-06-2022
[32]
ANSM. News - Update on the monitoring of vaccines against COVID-19 - Period from 30/09/2022 to 20/10/2022. 2022. Available from: https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-COVID-19-periode-du-30-09-2022-au-20-10-2022
[33]
OPECST. Report on “The adverse effects of vaccines against COVID-19 and the french pharmacovigilance system. 2022. Available from: https://www2.assemblee-nationale.fr/15/les-delegations-comite-et-office-parlementaire/office-parlementaire-d-evaluation-des-choix-scientifiques-et-technologiques/secretariat/a-la-une/rapport-sur-les-effets-indesirables-des-vaccins-contre-la-COVID-19-et-le-systeme-de-pharmacovigilance-francais
[34]
Buergin N, Lopez-Ayala P, Hirsiger JR, et al. Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination. Eur J Heart Fail 2023; n/a(n/a).
[http://dx.doi.org/10.1002/ejhf.2978]
[35]
Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: A vaccine recipient survey. Life 2021; 11(3): 249.
[http://dx.doi.org/10.3390/life11030249] [PMID: 33803014]
[36]
Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect Dis 2021; 21(7): 939-49.
[http://dx.doi.org/10.1016/S1473-3099(21)00224-3] [PMID: 33930320]
[37]
Tompkins LK, Baggs J, Myers TR, et al. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults. Vaccine 2022; 40(52): 7653-9.
[http://dx.doi.org/10.1016/j.vaccine.2022.10.073] [PMID: 36372665]
[38]
Rolfes L, Härmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F. COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes. Vaccine 2022; 40(7): 970-6.
[http://dx.doi.org/10.1016/j.vaccine.2022.01.013] [PMID: 35067381]
[39]
Pfizer. Comirnaty (COVID-19 MRNA Vaccine) - Risk Management Plan. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf
[40]
Seneff S, Nigh G. Worse than the disease? reviewing some possible unintended consequences of the mRNA Vaccines against COVID-19. Int J Vaccine, Theory. Pract Res 2021; 2(1): 38-79.
[http://dx.doi.org/10.56098/ijvtpr.v2i1.23]
[41]
Sainton J. Assessment of comirnaty injections of pregnant women in the manufacturer’s risk management plan and by the European Medicines Agency: Mandatory injections for caregivers in France. Int J Vaccine, Theory. Pract Res 2023; 3(1): 911-28.
[http://dx.doi.org/10.56098/ijvtpr.v3i1.72]
[42]
Pfizer. Comirnaty (COVID-19 MRNA Vaccine) - Risk Management Plan - Version Number: 2.0.; 2021. 2021. Available from: https://web.archive.org/web/20210602082901/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf
[43]
Pfizer. Comirnaty (COVID-19 MRNA Vaccine) - Risk Management Plan - Version Number: 5.0.; 2022. 2022. Available from: https://web.archive.org/web/20220415130551/https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf
[44]
Suarez Castillo M, Khaoua H, Courtejoie N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro Surveill 2022; 27(16): 2200250.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.16.2200250] [PMID: 35451363]
[45]
Carazo S, Skowronski DM, Brisson M, et al. Protection against Omicron BA.2 reinfection conferred by primary omicron or pre-Omicron infection with and without mRNA vaccination. medRxiv
[http://dx.doi.org/10.1101/2022.06.23.22276824]
[46]
Altarawneh HN, Chemaitelly H, Ayoub HH, et al. 1966. Protection afforded by prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections. Open Forum Infect Dis 2022; 9(S2): ofac492.1591.
[http://dx.doi.org/10.1093/ofid/ofac492.1591]
[47]
Davies MA, Morden E, Rousseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. Int J Infect Dis 2023; 127: 63-8.
[http://dx.doi.org/10.1016/j.ijid.2022.11.024] [PMID: 36436752]
[48]
Carazo S, Skowronski DM, Brisson M, et al. Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination. medRxiv
[http://dx.doi.org/10.1101/2022.04.29.22274455]
[49]
Eythorsson E, Runolfsdottir HL, Ingvarsson RF, Sigurdsson MI, Palsson R. Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. JAMA Netw Open 2022; 5(8): e2225320.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.25320] [PMID: 35921113]
[50]
Lin DY, Gu Y, Xu Y, et al. Effects of vaccination and previous infection on omicron infections in children. N Engl J Med 2022; 387(12): 1141-3.
[http://dx.doi.org/10.1056/NEJMc2209371] [PMID: 36069811]
[51]
Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infect Dis 2019; 10(6): ofad209.
[http://dx.doi.org/10.1093/ofid/ofad209]
[52]
Chemaitelly H, Nagelkerke N, Ayoub HH, et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection in Qatar. medRxiv
[http://dx.doi.org/10.1101/2022.07.06.22277306]
[53]
Public Health France. National census of COVID-19 cases among professionals in health establishments. 2022. Available from: https://www.santepubliquefrance.fr/etudes-et-enquetes/recensement-national-des-cas-de-COVID-19-chez-les-professionnels-en-etablissements-de-sante
[54]
Bamaze N’Gani E. The obligation to vaccinate against COVID-19: the contribution of a philosophical reflection. Stud Univ Babes-Bolyai - Stud Eur 2022; 67(1): 119-51.
[55]
Socol Y, Yanovskiy M, Shaki YY. Judeo-christian analysis of the COVID-19 crisis and its management. J Sociol Theory Relig 2023; 15(1): 131-54.
[http://dx.doi.org/10.24197/jstr.1.2023.131-154]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy